NLA 2020 Scientific Sessions On Demand

NLA Sessions On Demand Page Banner

For the first time ever, the National Lipid Association is pleased to offer our Virtual Scientific Sessions as an on-demand product. This year's Scientific Sessions were held live and virtual December 10-12 2020. If you could not attend those dates, you can still enjoy the conference at your convenience now through March 31, 2021

If you attended the live conference, you still have access to the on-demand version through January 11, 2021. You may not claim credit for both live and on-demand versions of this activity.

Register for 2020 Virtual Annual Scientific Sessions Enduring

Purchase Options

NLA Member Pricing
*Must be logged in

Main Session

December 14, 2020 - March 31, 2021

Non-Member Pricing

Main Session

December 14, 2020 - March 31, 2021

Trainee Pricing
*Must be logged in

Main Session

December 14, 2020 - March 31, 2021

Interested in the Trainee Rate?

Enrolled in a graduate or postgraduate training program and want to attend at the Trainee Member rate?

Apply now for free

Included Sessions

Please note that the agenda provided below includes the original presentation times to help you find specific content items. All sessions can be viewed at any time for the duration of your content purchase through March 31, 2021. Only accredited presentations are listed. Additional programs such as Expert Theaters and Satellite Symposia may be available to view for all or part of your purchase window; but they are NOT available for credit and their ongoing availability is NOT guaranteed.
Thursday, December 10, 2020
9:35AM - 9:45AM Opening Remarks
9:45AM - 11:10AM Session I- Cardiovascular Preventive Care in Pregnancy

9:50AM - 10:10AM

Pregnancy and Contraception - How Should we Counsel Women with Severe Dyslipidemia? Jennifer L.  Thompson, MD
10:10AM - 10:30AM Medical Therapy during Pregnancy Pamela B. Morris, MD, FNLA*
10:30AM - 10:50AM Medical Nutrition Therapy During High Risk Pregnancy with Severe Hypertriglyceridemia Wahida Karmally, PhD, MS, RDN, CDE, CLS
10:50AM - 11:10AM Question & Answer Panel
11:15AM - 1:00PM Session II- Ethical Dilemmas in Lipidology
11:20AM - 11:40AM CVD Risk Reduction – Is Ovum Selection Ethical for FH? James A. Trippi, MD, FNLA*
11:40AM - 12:00PM Can we Justify FH Genetic Testing Prior to the Age of Consent? G. Kevin Donovan, MD, MA
12:00PM - 12:20PM Statins and Reproductive Health in Teens - An Accident Waiting to Happen? Ann Liebeskind, MD, FNLA*
12:20PM - 12:40PM Does Cholesterol Screening Potentially Limit Job Opportunities? Don P. Wilson, MD, FNLA*
12:40PM - 1:00PM Question & Answer Panel
4:00PM - 6:00PM NLA Opening Session – Impact of Genetics on Clinical Practice- Chair Dr. Christie Ballantyne
4:05PM - 4:15PM Case Presentation Aliza Hussain, MD
4:15PM - 4:35PM Genetic Testing for Lipid Disorders Zahid Ahmad, MD
4:35PM - 4:55PM Polygenic Risk Scores for CVD, Use in Practice and Potential Impact on Healthcare Joshua W. Knowles, MD
4:55PM - 5:15PM My Patients are Ordering Direct-to-Consumer Genetic Testing- What Now? Emily E. Brown, MGC, CGC
5:15PM - 5:35PM Genetics and Biotech therapies Christie M. Ballantyne, MD, FNLA*
5:40PM - 6:00PM Question & Answer Panel
Friday, December 11, 2020
8:50AM - 9:00AM Opening Remarks
9:00AM - 10:25AM Session III- Non-Alcoholic Fatty Liver Disease and Risk of Cardiovascular Disease: What Clinicians Need to Know
9:05AM - 9:15AM Case Presentation of Patient with Non-Alcoholic Fatty Liver Disease Pam R. Taub, MD
9:15AM - 9:35AM Diagnosing NAFLD and NASH in Clinical Practice and When to Refer to a Specialist John M. Vierling, MD
9:35AM - 9:50AM Evidence Based Drug Therapy Treatment Options for NAFLD Michael Wilkinson, MD
9:50AM - 10:10AM Lifestyle Interventions for NAFLD: Evaluation of the Evidence Lisa B. VanWagner, MD, MSc
10:10AM - 10:25AM Question & Answer Panel
10:30AM - 10:55AM NLA Presidents Address
10:55AM - 11:30AM W. Virgil Brown Distinguished Award and Lectureship John R. Guyton, MD, FNLA
12:05PM - 1:30PM Session IV- Imaging Atherosclerosis: What We Know and Gaps in Knowledge
12:10PM - 12:30PM

Tracking Atherosclerosis with Cardiac CT

Matthew J. Budoff, MD
12:30PM - 12:50PM Carotid Ultrasound and Brachial FMD James H. Stein, MD
12:50PM - 1:10PM Imaging in Pediatrics- Where we Are and Where we Need to go Elaine M. Urbina, MD, MS
1:10PM - 1:30PM Question & Answer Panel
2:40PM - 4:05PM Session V- Let’s Talk About Sex…Hormones
2:45PM - 3:05PM Hormone Replacement in Postmenopausal Women: Panacea or Poison? Eliot A. Brinton, MD, FNLA
3:05PM - 3:25PM Testosterone Treatment in Men Maamoun Salam, MD
3:25PM - 3:45PM Effects of Hormonal Therapy for Transgender Transition Eugenia Gianos, MD, FNLA
3:45PM - 4:05PM Question & Answer Panel
4:15PM - 5:40PM Session VI- Prevention of Atherosclerotic Cardiovascular Disease in South Asians in the US
4:20PM - 4:40PM Epidemic of ASCVD in South Asians in the US and Strategies for Early Identification Dinesh Kalra, MD
4:40PM - 5:00PM Diabetes and Heart Disease in South Asians in the US:  Challenges and Opportunities in Management Krishnaswami Vijayaraghavan, MD, MS, FNLA
5:00PM - 5:20PM Dyslipidemia in South Asians in the US Nihar R. Desai, MD, MPH
5:20PM - 5:40PM Question & Answer Panel
Saturday, December 12, 2020
10:10AM - 10:20AM Opening Remarks
1:30PM - 3:00PM Non-CME Special Joint Session between EAS and NLA- Dyslipidemia Treatment in Light of the New Guidelines- Chairs: Lale Tokgözoğlu, MD and Antonio M. Gotto, Jr., MD, DPhil, FNLA
1:30PM - 1:35PM Session Introduction from Chairs  
Targets and Goals
1:35PM - 1:50PM EAS Perspectives Alberico L. Catapano, PhD
1:50PM - 2:05PM NLA Perspectives Carl E. Orringer, MD, FNLA
Therapeutic Approaches
2:05PM - 2:50PM EAS Recommendations & Perspectives Lale Tokgözoğlu, MD
2:50PM - 2:35PM NLA Recommendations & Perspectives Peter H. Jones, MD, FNLA
2:35PM - 3:00PM Question & Answer Panel
3:05PM - 4:05PM Session IX- Scientific Statements
3:05PM - 3:10PM Introduction of the NLA Scientific Statement on CAC Carl E. Orringer, MD, FNLA
3:10PM - 3:30PM NLA Scientific Statement on CAC: CAC Testing and Interpretation Matthew J. Budoff, MD
3:30PM - 3:50PM NLA Scientific Statement on CAC: CAC Guided Treatment Recommendations and other Considerations Michael Blaha, MD
3:50PM - 4:05PM Question & Answer Panel
4:05PM - 4:25PM Junior Faculty Research Award Presentation Nathan Stitziel, MD, PhD
4:30PM - 5:20PM Late Breakers


Accreditation Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.5 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this Internet Enduring Activity for a maximum of 12.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.5 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.

Pharmacist Accreditation Statement

Universal Activity Number JA0007192-0000-20-029-H04-P (Application)
This Activity has been approved for 12.5 contact hour(s) (1.250 CEUs) of the Accreditation Council for Pharmacy Education

The maximum number of hours awarded for this CE activity is 12.6 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.


Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.

Type of Activity
Internet Enduring Activity, Application

Educational Objectives

At the conclusion of this activity, all participants should be able to:

  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

Session I: Cardiovascular Preventive Care in Pregnancy

  • Discuss potential cardiovascular risks associated with pregnancy in women with genetic dyslipidemia.
  • Review strategies for managing CVD risk in pregnant women or women who plan to become pregnant.

Session II: Ethical Dilemmas in Lipidology

  • Discuss ethical controversies in the practice of lipidology.

NLA Opening Session: Impact of Genetics on Clinical Practice

  • Evaluate the use of genetic testing to inform risk assessment and therapeutic decisions.
  • Explain the role of the genetic counselor in screening for genetic disorders.
  • Review challenges in the application of genomic testing into clinical practice.
  • Apply insight from human genetics to identify novel therapeutic targets.

Session III: Non-Alcoholic Fatty Liver Disease and Risk of Cardiovascular Disease: What Clinicians Need to Know

  • Identify appropriate lipid management for patients with non-alcoholic fatty liver disease.
  • Review appropriate diagnostic strategies in patients with non-alcoholic fatty liver disease.
  • Determine therapeutic options for the treatment of non-alcoholic fatty liver disease.

W. Virgil Brown Distinguished Achievement Award and Lectureship

  • Evaluate the management of patients with dyslipidemia.

Session IV: Imaging Atherosclerosis: What We Know and Gaps in Knowledge

  • Review the use of imaging modalities for cardiovascular risk assessment.

Session V: Let’s Talk About Sex…Hormones

  • Discuss the efficacy and safety of hormonal therapies in the management of dyslipidemia and cardiovascular risk.

Session VI: Prevention of Atherosclerotic Cardiovascular Disease in South Asians in the US

  • Recognize the risk factors and interconnection of early onset diabetes and ASCVD in South Asians.
  • Discuss epidemiology and risk profiles for dyslipidemia in South Asians in the United States.

Session VII: Oral Poster Presentations

  • Critically appraise emerging research and its applications to daily clinical practice.

Session IX: Scientific Statements of the NLA

  • Review current literature of importance to the science and practice of clinical lipidology.

NLA Junior Faculty Research Award Presentation

  • Discuss the recent research impacting future management of patients with dyslipidemia.
Publish Date: 
Monday, December 14, 2020 - 15:30

This page was last updated: Dec 15, 2020